Results 101 to 110 of about 6,510 (202)

Incidence of COVID-19 Symptom Rebound After Treatment with Remdesivir

Infectious Disease Reports
Background/Objectives: Recent in vitro data suggest that remdesivir might be less likely than nirmatrelvir–ritonavir to be associated with COVID-19 rebound. We compared the incidence of symptom rebound in our remdesivir-treated cohort with rates reported
Kalpana Gupta, William J. O’Brien, Judith Strymish, Anna Chen, Katherine Linsenmeyer, Rebecca Madjarov, Michael E. Charness   +6 more
doaj   +1 more source

Nirmatrelvir-ritonavir for COVID-19 [PDF]

Canadian Medical Association Journal, 2022
McDonald, Emily G, Lee, Todd C
openaire   +2 more sources

Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia

BMC Infectious Diseases
Background The effect of nirmatrelvir/ritonavir on preventing post-COVID condition (PCC) in the BA4, BA5, and XBB Omicron predominant periods is not well understood.
Ee Vien Low, Mohan Dass Pathmanathan, Yi Yang Ten, Suresh Kumar Chidambaram, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Mastura Ismail, Azah Abdul Samad, Kalaiarasu M. Peariasamy   +10 more
doaj   +1 more source

Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug–drug interactions

Journal of International Medical Research
Nirmatrelvir/ritonavir is a novel drug combination that is authorized by the Food and Drug Administration for the treatment of coronavirus disease 2019 (COVID-19).
Dan Shen, Yinhua Gong, Yulan Qian, Jianguo Zhu, Jie Gao   +4 more
doaj   +1 more source

Clin Infect Dis [PDF]

Background:Nirmatrelvir/ritonavir (N/R) reduces severe outcomes among patients with COVID-19; however, rebound after treatment has been reported. We compared symptom and viral dynamics in community-based individuals with COVID-19 who completed N/R and ...

core  

Proceed With Caution: Drug Interaction Complicates Use of Nirmatrelvir/Ritonavir in Kidney Transplant Recipients With COVID-19 [PDF]

, 2023
Shailly, Shikha, et. al.
core   +2 more sources

Management of infectious diseases in the immunocompromised host:from A-(spergillus) to C-(OVID19) [PDF]

People with weakened immune systems, especially patients with hematological malignancies, are at a higher risk for infectious diseases, which often present with severe outcomes. COVID-19 is one of these infectious diseases.
Huygens, Sammy
core   +2 more sources

Managing High-Risk Drug Interactions With Nirmatrelvir/Ritonavir: Experience From a Dedicated Pharmacology Advice Service. [PDF]

Clin Transl Sci
Libiad Y, Franck B, Tron C, Lalanne S, Boglione-Kerrien C, Taïeb F, Verdier MC, Lemaitre F.   +7 more
europepmc   +1 more source

A real-world retrospective analysis comparing the effectiveness of Azvudine and Nirmatrelvir/Ritonavir in COVID-19 patients with diabetes. [PDF]

Sci Rep
Zhu Z, Chen Q, Wang Z, Chen Q, Li X, Liu Y, Lu H, Feng J, Xie M, Dong X, Chen B, Huang J, Zeng X, Zeng Z, Yuan Y, Xu F, Liao X, Liang B, Chen W.   +18 more
europepmc   +1 more source

Nirmatrelvir/Ritonavir-Induced Calcium Channel Blocker Intoxication Successfully Treated by High Dose Insulin Therapy. [PDF]

Acta Cardiol Sin
Chen CY, Cia CT.
europepmc   +1 more source